This is the first reported series of intentional infliximab use throughout pregnancy.
Dr Mahadevan and colleagues aimed to study the effects of infliximab on pregnancy and fetal outcome.
|All 10 pregnancies ended in live births and no infants had congenital malformations|
|Alimentary Pharmacology & Therapeutics|
The team’s primary outcome measure was the occurrence of congenital malformations.
The investigative team conducted a retrospective chart review of women with Crohn's disease treated intentionally with infliximab during pregnancy.
The investigators also considered secondary outcome measures including the rate of premature birth, low-birth weight, small for gestational age infants, intrauterine growth retardation and cesarean section.
10 women were identified, 8 of which received maintenance infliximab infusions throughout their pregnancy and 2 received their initial infliximab infusions during pregnancy.
The researchers reported that all 10 pregnancies ended in live births and no infants had congenital malformations, intrauterine growth retardation or were small for gestational age parameters.
The team also noted that 3 infants were premature, 1 had low-birth weight and 8 women had a cesarean section.
Dr Mahadevan concludes, “These data, combined with other studies of inadvertent use of infliximab during pregnancy, suggest that the benefits of infliximab in achieving response and maintaining remission in mothers with Crohn's disease may outweigh the risk to the fetus of exposure to the drug.”
“Further prospective data collection will be helpful to confirm these findings.”